Chief Operating Officer

Dr Mark Devlin

Mark took on the role of Chief Operating Officer for Cancer Therapeutics CRC in June 2018.  Prior to this Mark had led the CRC’s Translational Cancer Biology group at the Peter MacCallum Cancer Centre since 2008. Mark has worked in a variety of roles focused on academic-based drug discovery and development in a number of therapeutic areas including, pain, inflammation, autoimmune disease and oncology.

He is a former founder and director of Ocean Pharmaceuticals, and co-founder of Amplia Therapeutics that has recently been acquired by the ASX-listed company Innate Immunotherapeutics to advance the small molecule FAK inhibitors originally developed by the CRC.

Mark has a PhD in Pharmacology from the University of Melbourne, a post-graduate diploma in drug development from the University of New South Wales and is currently completing a MBA at the Melbourne Business School.